Readystate Asset Management LP Takes $526,000 Position in Inhibrx, Inc. (NASDAQ:INBX)

Readystate Asset Management LP purchased a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 13,839 shares of the company’s stock, valued at approximately $526,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. RA Capital Management L.P. grew its holdings in shares of Inhibrx by 22.6% during the third quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock worth $86,689,000 after purchasing an additional 870,340 shares in the last quarter. Perceptive Advisors LLC grew its holdings in shares of Inhibrx by 9.1% during the first quarter. Perceptive Advisors LLC now owns 3,615,383 shares of the company’s stock worth $68,222,000 after purchasing an additional 301,600 shares in the last quarter. BlackRock Inc. boosted its stake in Inhibrx by 9.2% in the second quarter. BlackRock Inc. now owns 2,546,603 shares of the company’s stock worth $66,110,000 after buying an additional 213,678 shares in the last quarter. State Street Corp boosted its stake in Inhibrx by 282.7% in the third quarter. State Street Corp now owns 2,040,054 shares of the company’s stock worth $36,619,000 after buying an additional 1,506,986 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Inhibrx by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 1,874,323 shares of the company’s stock worth $71,224,000 after buying an additional 84,512 shares in the last quarter. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Trading Down 0.5 %

INBX stock traded down $0.16 during midday trading on Thursday, hitting $34.45. The company had a trading volume of 415,786 shares, compared to its average volume of 698,410. The company has a current ratio of 5.24, a quick ratio of 5.25 and a debt-to-equity ratio of 4.78. Inhibrx, Inc. has a 52 week low of $14.31 and a 52 week high of $39.79. The stock’s 50 day moving average price is $35.98 and its 200 day moving average price is $29.54. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -6.87 and a beta of 2.91.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.66). Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, equities research analysts expect that Inhibrx, Inc. will post -4.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

INBX has been the subject of several research reports. JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research note on Tuesday, January 23rd. Lifesci Capital lowered Inhibrx from an “outperform” rating to a “market perform” rating in a research note on Tuesday, January 23rd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.